The strong revenue growth and profitability inflection, combined with the clean balance sheet post-convertible note conversion, support a bullish thesis. Watch for continued YORVIPATH uptake and the upcoming EMA decision on YUVIWEL in Q4 2026, which could drive further upside. The stock's addition to Russell indexes may also attract passive inflows.
Drugs in focus
ASND drug pipeline →lonapegsomatropin
● Neutral Named in this press release- Impact
- Phase
- Approved
- Time to market
- Already approved and marketed (FDA approval August 2021)
- Next catalyst
- None dated
What to watchSkytrofa is a steady commercial contributor but not the primary value driver for ASND anymore, YORVIPATH's rapid growth and the YUVIWEL launch are the main catalysts. Watch for any FDA filing for adult GHD indication (completed Phase 3 data in hand) and quarterly Skytrofa sales trajectory. The stock's next major binary catalyst is the EU MAA decision for YUVIWEL expected in Q4 2026.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 13 $246.23entry
- T+1 · 3mo ago +0.92%α +1.12% · $248.50
- T+5 · 3mo ago +3.48%α +5.45% · $254.81
- T+20 · 2mo ago +7.02%α +8.77% · $263.52
- T+60 · 10d ago +4.30%α +9.78% · $256.82
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Ascendis Pharma reported Q2 2026 product revenue of €315M (+105% YoY), driven by YORVIPATH (€252M) and SKYTROFA (€55M), and achieved its first-ever operating profit of €220M (65% margin). The company also settled all $575M in convertible notes, converting them to equity, and reported non-IFRS diluted EPS of €0.90, which is in line with the Street consensus of $0.77 (€0.71), a modest beat. The strong top-line growth and profitability inflection are the key drivers, but the GAAP EPS of €2.83 includes a one-time €158M PRV sale and a €704M deferred tax asset recognition, masking underlying operating leverage.
Key Financial Metrics
Key Facts
- Q2 2026 total revenue €339M vs €158M YoY (+115%)
- Product revenue €315M, +105% YoY, driven by YORVIPATH €252M (+145% YoY)
- First-ever operating profit of €220M (65% margin) vs operating loss of €53M YoY
- Non-IFRS operating profit €92M (27% margin) vs non-IFRS operating loss of €23M YoY
- Non-IFRS diluted EPS €0.90 vs consensus $0.77 (~€0.71), a ~27% beat
- Converted all $575M of 2.25% Convertible Senior Notes due 2028 to equity, eliminating €719M in liabilities
- Cash and equivalents €812M as of June 30, 2026, up from €616M at Dec 31, 2025
- YUVIWEL revenue €8M with >220 unique patient enrollments in the U.S.
- Added to Russell 3000, 1000, 2500, and Midcap Indexes in June 2026
Financial Impact
Product revenue growth of 105% YoY to €315M; operating profit swing of +€273M YoY; non-IFRS EPS beat of ~27% vs consensus
Risk Factors
- Revenue growth is heavily dependent on YORVIPATH (80% of product revenue); any competitive or reimbursement headwind could slow momentum
- SG&A expenses rose 61% YoY to €173M, reflecting commercial expansion costs that may pressure margins if revenue growth decelerates
- Non-IFRS adjustments are significant, GAAP net profit includes €158M one-time PRV sale and €704M deferred tax asset recognition, which are non-recurring
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3344408 |
Track record
41 reports on ASND
13 of 18 bullish or bearish reports moved the stock their way by T+60. Best: +26.62% at T+20 after the Jun 2, 2026 report. 24 of 26 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $271.96 Now $271.73 −0.08% settles Feb 12
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $275.39 Now $271.73 −1.33% settles Feb 11
- Nov 12, 20264d ago 6-K Bullish 6/10 Entry $267.07 Now $271.73 +1.74% settles Feb 10
- Nov 12, 20264d ago Press Release Neutral 5/10 Entry $267.07 Now $271.73 +1.74% settles Feb 10
- Nov 6, 202610d ago 6-K Bullish 6/10 Entry $259.85 Now $271.73 +4.57% settles Feb 5
- Nov 6, 202610d ago Press Release Bullish 6/10 Entry $256.82 Now $271.73 +5.81% settles Feb 4
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $253.45 Now $271.73 +7.21% settles Feb 3
- Nov 2, 202613d ago Institutional Cluster Bullish 4/10 Entry $250.17 Now $271.73 +8.62% settles Feb 1
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $245.85 Now $271.73 +10.53% settles Jan 25
- Oct 16, 20264w ago 6-K Bullish 7/10 Entry $225.25 Now $271.73 +20.63% settles Jan 13
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers